January 7th, 2022
Inimmune (Missoula, MT), a biotechnology company focused on devleoping the next generation of vaccines and immunotheraputics, has appointed Jon Ruckle, M.D. as Chief Medical Officer. Dr. Ruckle brings over 25 years of clinical trial experience including protocol design, product development strategy, and medical monitoring. He has served as an Investigator for over 350 clinical trials. Dr. Ruckle will oversee the global clinical development and regulatory activites for Inimmune.
After receiving his medical degree from Loma Linda University and completing an Internal Medicine Residency at Mayo Clinic, Dr. Ruckle served as the founding Medical Director at Northwest Kinetics in Tacoma, WA, from 1995 to 2000. He then led Phase I development at Radiant Research Honolulu from August 2000 until acquired by Covance in 2006. He remained as Medical Director at Covance until 2008, then fouded Pacific Pharma Group in 2008 and served as Medical Director, Early Development for Comprehensive Clincical Development in Tacoma, WA from 2011 to 2013.
”We are excited to welcome Dr. Ruckle to the Inimmune team. His expertise in clinical trial deisgn and implementation will help accelerate Inimmune’s transition from a pre-clinical to clinical stage biopharmaceutical company” said Jay Evans, CEO.
About Inimmune Corp.
Inimmue is a promising biotechnology company founded in 2016 by an experienced team of pharmaceutical industry leaders. The team has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Inimmune’s pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy, infectious disease vaccines, and novel antibiotics for bacterial infections.
For more information about Inimmune please visit https://inimmune.com/